Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Julphar
Covington
Queensland Health
Argus Health
McKinsey
Johnson and Johnson
Farmers Insurance
Chinese Patent Office

Generated: June 24, 2018

DrugPatentWatch Database Preview

Bristol Company Profile

« Back to Dashboard

Drugs and US Patents for Bristol

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb BARACLUDE entecavir TABLET;ORAL 021797-002 Mar 29, 2005 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb AMITID amitriptyline hydrochloride TABLET;ORAL 086454-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Bristol TETREX tetracycline phosphate complex CAPSULE;ORAL 061653-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Bristol TETREX tetracycline phosphate complex CAPSULE;ORAL 061653-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Bristol

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb MONOPRIL fosinopril sodium TABLET;ORAL 019915-004 Mar 28, 1995 4,384,123 ➤ Try a Free Trial
Bristol Myers Squibb VIDEX EC didanosine CAPSULE, DELAYED REL PELLETS;ORAL 021183-002 Oct 31, 2000 5,254,539*PED ➤ Try a Free Trial
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-003 Sep 17, 1998 5,811,423 ➤ Try a Free Trial
Bristol Myers Squibb PRAVIGARD PAC (COPACKAGED) aspirin; pravastatin sodium TABLET, TABLET, TABLET;ORAL 021387-003 Jun 24, 2003 4,346,227*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BRISTOL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Capsules 200 mg, 250 mg and 400 mg ➤ Subscribe 2004-06-01
➤ Subscribe Tablets 30 mg ➤ Subscribe 2005-06-01
➤ Subscribe Capsules 100 mg and 150 mg ➤ Subscribe 2010-03-19
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-06-14
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 2011-06-16
➤ Subscribe Nasal Spray 4 mg/spray ➤ Subscribe 2016-07-15
➤ Subscribe Capsules 50 mg, 100 mg and 200 mg ➤ Subscribe 2016-11-03
➤ Subscribe Tablets 600 mg ➤ Subscribe 2009-04-09
➤ Subscribe Capsules 300 mg ➤ Subscribe 2009-07-20
➤ Subscribe Capsules 200 mg ➤ Subscribe 2010-02-16
➤ Subscribe Tablets 20 mg, 50 mg, 70 mg and 100 mg ➤ Subscribe 2010-06-28
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 2011-06-17
➤ Subscribe Tablets 2.5 mg and 5 mg ➤ Subscribe 2016-12-28

Non-Orange Book US Patents for Bristol

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,979,694 Cyclic protein tyrosine kinase inhibitors ➤ Try a Free Trial
8,470,854 Lactam-containing compounds and derivatives thereof as factor XA inhibitors ➤ Try a Free Trial
7,338,963 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Try a Free Trial
9,758,487 Hepatitis C virus inhibitors ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Bristol Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1730131/02 Switzerland ➤ Try a Free Trial PRODUCT NAME: EMPAGLIFLOZIN UND METFORMINHYDROCHLORID; REGISTRATION NO/DATE: SWISSMEDIC 65570 12.11.2015
2015040,C2049506 Lithuania ➤ Try a Free Trial PRODUCT NAME: KOBICISTATAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/13/830/001 - 002 20130524
C0046 Belgium ➤ Try a Free Trial PRODUCT NAME: DOXORUBICIN HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/96/011/001 19960624
60026 Netherlands ➤ Try a Free Trial PRODUCT NAME: INSULINUM LISPRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/96/007/001 - EU/1/96/007/003 19960430
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Deloitte
Healthtrust
Farmers Insurance
QuintilesIMS
Chinese Patent Office
Boehringer Ingelheim
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.